Abstract | OBJECTIVES:
Gonadotropin-releasing hormone agonists increase fat mass, decrease insulin sensitivity, and increase serum triglycerides. To better characterize the metabolic effects of gonadotropin-releasing hormone agonist treatment, we prospectively evaluated the changes in body composition, insulin sensitivity, and levels of adiponectin, resistin, C-reactive protein (CRP), and plasminogen activator inhibitor type 1 (PAI-1). We also assessed the relationships among changes in adipocytokines, body composition, and insulin sensitivity. METHODS: RESULTS: The mean +/- standard error percentage of fat body mass increased by 4.3% +/- 1.3% from baseline to week 12 (P = 0.002). The insulin sensitivity index decreased by 12.9% +/- 7.6% (P = 0.02). The serum adiponectin levels increased by 37.4% +/- 7.2% from baseline to week 12 (P <0.001). In contrast, the resistin, CRP, and PAI-1 levels did not change significantly. Changes in body composition tended to be associated with changes in adiponectin, but not insulin sensitivity. CONCLUSIONS:
|
Authors | Matthew R Smith, Hang Lee, Mary Anne Fallon, David M Nathan |
Journal | Urology
(Urology)
Vol. 71
Issue 2
Pg. 318-22
(Feb 2008)
ISSN: 1527-9995 [Electronic] United States |
PMID | 18308111
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adipokines
- Androgen Antagonists
- Anilides
- Antineoplastic Agents, Hormonal
- Nitriles
- Tosyl Compounds
- bicalutamide
- Leuprolide
|
Topics |
- Adipokines
(blood)
- Aged
- Androgen Antagonists
(therapeutic use)
- Anilides
(therapeutic use)
- Antineoplastic Agents, Hormonal
(therapeutic use)
- Body Composition
- Drug Therapy, Combination
- Humans
- Insulin Resistance
- Leuprolide
(therapeutic use)
- Male
- Nitriles
(therapeutic use)
- Obesity
(complications)
- Prospective Studies
- Prostatic Neoplasms
(complications, drug therapy, metabolism)
- Tosyl Compounds
(therapeutic use)
|